Special Issue

Advances in Drug Treatment for Leishmaniasis

Message from the Guest Editor

Globally distributed and closely related to poverty, the leishmaniases are neglected tropical diseases, with more than 1 billion people at risk of infection. Given the difficulties associated with vector control and the absence of an effective vaccine, leishmaniasis control relies primarily on chemotherapy. Nevertheless, current therapies have severe shortcomings, highlighting an urgent need for innovative safe and efficacious treatments, understanding the mechanism of resistance to preserve the current available drugs, and the development of innovative approaches for disease control. This Special Issue aims to gather relevant manuscripts, from basic to translational studies, to cover different aspects of the recent advances in drug treatment for leishmaniasis; current chemotherapy and recent advances in drug treatment for leishmaniasis; drug combination; immunotherapy; drug-delivery systems for the treatment of leishmaniasis; target identification and validation in Leishmania, drug development for leishmaniasis; drug resistance to leishmaniasis; mechanisms of drug action and drug resistance; prognostic markers for leishmaniasis treatment and diagnosis; etc.

Guest Editor

Dr. Juliana Carnielli

York Biomedical Research Institute, Department of Biology, University of York, York YO10 5DD, UK

Deadline for manuscript submissions

closed (15 June 2023)



Tropical Medicine and Infectious Disease

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 3.9
Indexed in PubMed



mdpi.com/si/142327

Tropical Medicine and Infectious Disease MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 tropicalmed@mdpi.com

mdpi.com/journal/ tropicalmed





Tropical Medicine and Infectious Disease

an Open Access Journal by MDPI

Impact Factor 2.8 CiteScore 3.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. John Frean

Pathologist, Parasitology Reference Lab, Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases, University of the Witwatersrand, Johannesburg 2192, South Africa

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Informit, and other databases.

Journal Rank:

JCR - Q1 (Tropical Medicine) / CiteScore - Q2 (Public Health, Environmental and Occupational Health)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.9 days after submission; acceptance to publication is undertaken in 4.8 days (median values for papers published in this journal in the first half of 2024).

